"Q. Firstly, just going to another pipeline asset, iscalimab. Wonder if you could just give us a bit of clarity on the path forward for filing of that now. I see your commentary that the regulatory interactions suggest that you can't file, you don't think, based on kidney transplant \u2013 sorry, based on the ongoing study. And so what is the planned time line there? Can you use liver and kidney together? Or has another trial started or planned to be started? And how do you think about that? And what sort of endpoints are the regulators requiring?"